I realize this is just another fibonacci speculation, which haven't turned out to be very accurate. But I wouldn't be surprised if this turned out to be true. Amarantus is not a diagnostic expert. Maybe they never intended to be. Maybe that is why they really haven't tried very hard getting sales for Lympro. Maybe they just needed to assemble enough critical mass to sell the division and move on with MANF, Eltoprazine, and ESS.
I guess we'd get some cash. I have no idea how much. 50 million would be a minimum, but 500 million would be nice. And we'd get some royalties.
I think the sale of the entire division is a scenario that would make sense out of the lack of LymPro sales and Gerald's quite period. Let's hope.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links